Patents by Inventor Martine Marchand

Martine Marchand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10639361
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: May 5, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Patent number: 10493145
    Abstract: Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: December 3, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Guy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
  • Publication number: 20190307872
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Inventor: Martine MARCHAND
  • Patent number: 10350283
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: July 16, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Publication number: 20190076519
    Abstract: Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.
    Type: Application
    Filed: August 17, 2018
    Publication date: March 14, 2019
    Applicant: GlaxoSmithKline Biologicals S.A.
    Inventors: Guy BAUDOUX, Mathieu BOXUS, Brigitte COLAU, Martine MARCHAND
  • Publication number: 20190030154
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 31, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine MARCHAND
  • Patent number: 10105430
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: October 23, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Patent number: 10058603
    Abstract: The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Guy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
  • Publication number: 20170196961
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 13, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventor: Martine MARCHAND
  • Patent number: 9655958
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 23, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Rhea Coler, Steven Reed, Yves Lobet, Martine Marchand
  • Patent number: 9592282
    Abstract: The present invention relates to a novel hybrid/fusion protein derived from the CS protein of Plasmodium vivax (P. vivax), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by P. vivax, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of P. vivax, b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of P. vivax, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: March 14, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Joseph D. Cohen, Martine Marchand, Christian F. Ockenhouse, Anjali Yadava
  • Patent number: 9364525
    Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), and c. optionally the S antigen derived from Hepatitis B.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: June 14, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Joseph D. Cohen, Martine Marchand, Christian F. Ockenhouse, Anjali Yadava
  • Publication number: 20160022803
    Abstract: The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Guy BAUDOUX, Mathieu BOXUS, Brigitte COLAU, Martine MARCHAND
  • Patent number: 8999347
    Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterized in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: April 7, 2015
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Joseph D Cohen, Martine Marchand
  • Publication number: 20140056967
    Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.
    Type: Application
    Filed: August 13, 2013
    Publication date: February 27, 2014
    Applicants: GlaxoSmithKline Biologicals S.A., Corixa Corporation
    Inventors: Brenda Barth, India Ajay, Mark Alderson, Jean-Francois L. Maisonneuve, Yves Lobert, Florence Bernadette Nozay, Martine Marchand, Pascal Mettens, Yasir A. Skeiky, Peter Probst
  • Patent number: 8541007
    Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: September 24, 2013
    Assignees: GlaxoSmithKline Biologicals S.A., Corixa Corporation
    Inventors: Mark Alderson, Ajay Bhatia, Yves Lobet, Brenda Maisonneuve, Jean-Francois L Maisonneuve, Martine Marchand, Pascal Mettens, Florence Bernadette Nozay, Peter Probst, Samira H Skeiky
  • Publication number: 20130216613
    Abstract: The invention relates to a cytomegalovirus (CMV) gB polypeptide comprising at least a portion of a gB protein extracellular domain comprising a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, wherein at least one of the FL1 and FL2 domains comprises at least one amino acid deletion or substitution.
    Type: Application
    Filed: October 14, 2011
    Publication date: August 22, 2013
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Martine Marchand
  • Publication number: 20110300206
    Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.
    Type: Application
    Filed: December 21, 2010
    Publication date: December 8, 2011
    Applicants: GlaxoSmithKline Biologicals, sa, Corixa Corporation
    Inventors: Mark ALDERSON, Ajay BHATIA, Yves LOBET, Brenda MAISONNEUVE, Jean-Francois L. MAISONNEUVE, Martine MARCHAND, Pascal METTENS, Florence Bernadette NOZAY, Peter PROBST, Yasir A. SKEIKY, Samira H. SKEIKY
  • Publication number: 20100272786
    Abstract: The invention relates to a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from P. falciparum or a fragment thereof, for example as shown in Seq ID No: 1 or Seq ID No: 3. The invention also relates to processes of preparing said viral vector and use of the viral vector in the treatment/prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect the invention employs a synthetic C7 viral vector. The C7 viral vector according to the invention may be co-administered or co-formulated with a malaria antigen such as RTS,S optionally in the presence of an adjuvant for example comprising 3D-MPL and/or a saponin such as QS21.
    Type: Application
    Filed: June 12, 2008
    Publication date: October 28, 2010
    Inventors: Joseph D. Cohen, Martine Marchand
  • Publication number: 20100272788
    Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterised in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.
    Type: Application
    Filed: December 22, 2008
    Publication date: October 28, 2010
    Applicant: GlaxoSmithKline Biologicals s.a.
    Inventors: Joseph D. Cohen, Martine Marchand